Drugs / LB-100
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06012734 | Jun 2024 → Jul 2028 expected | colorectal cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04560972 | May 2021 → Jan 2027 expected | small cell lung carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01837667 | Feb 2013 → Sep 2016 | cancer | Lixte Biotechnology Holdings, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06065462 | Nov 2023 → Oct 2027 expected | ovarian clear cell cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05809830 | May 2023 → Jun 2025 overdue | soft tissue sarcoma | Spanish Group for Research in Sarcomas | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03886662 | Apr 2019 → May 2021 overdue | myelodysplastic syndrome | Lixte Biotechnology Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03027388 | Jan 2019 → Aug 2022 | giant cell glioblastoma, oligodendroglioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03886662 ↗ |
| Action | Inhibit | “Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor” CHEMBL4297300 ↗3“Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor” CHEMBL4297300 ↗ “LB-100, a first-in-class small-molecule inhibitor of protein phosphatase 2A (PP2A)” PMID 28039265 ↗ Dec 2016 “Serine/threonine-protein phosphatase 5 inhibitor” CHEMBL4297300 ↗ |
| Modality | Small molecule | “LB-100, a first-in-class small-molecule inhibitor of protein phosphatase 2A (PP2A)” PMID 28039265 ↗ Dec 2016 |
| Route | Intravenous | “LB-100 was administered intravenously daily for 3 days in 21-day cycles” PMID 28039265 ↗ Dec 2016 |
| Target | PPP2CA | “Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor” CHEMBL4297300 ↗ |
| Target | PPP2CB | “Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor” CHEMBL4297300 ↗ |
| Target | PPP5C | “Serine/threonine-protein phosphatase 5 inhibitor” CHEMBL4297300 ↗ |